✦ LIBER ✦

Imatinib dose escalation for chronic phase–chronic myelogenous leukaemia patients in primary suboptimal response to imatinib 400 mg daily standard therapy

✍ Scribed by Rea, D; Etienne, G; Corm, S; Cony-Makhoul, P; Gardembas, M; Legros, L; Dubruille, V; Hayette, S; Mahon, F-X; Cayuela, J-M

Book ID: 109887063
Publisher: Nature Publishing Group
Year: 2009
Tongue: English
Weight: 117 KB
Volume: 23
Category: Article
ISSN: 0887-6924
DOI: 10.1038/leu.2009.32

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase IV study evaluating efficacy of es

Phase IV study evaluating efficacy of escalated dose of imatinib in chronic myeloid leukemia patients showing suboptimal response to standard dose imatinib

✍ Youngil Koh; Inho Kim; Sung-Soo Yoon; Byoung Kook Kim; Dae-Young Kim; Je-Hwan Le 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 127 KB

Cytogenetic and molecular responses in c

Cytogenetic and molecular responses in chronic phase chronic myeloid leukaemia patients receiving low dose of imatinib for intolerance to standard dose

✍ Massimo Breccia; Laura Cannella; Caterina Stefanizzi; Roberto Latagliata; Mauro 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 76 KB

## Abstract Imatinib mesylate is the gold standard treatment of chronic myeloid leukaemia (CML) and 400 mg/day is considered the standard dose. Although it is generally well tolerated, some patients require temporary drug discontinuation and permanent dose reduction because of haematological or non

Thrombocytopenia Induced by Imatinib Mes

Thrombocytopenia Induced by Imatinib Mesylate (Glivec) in Patients with Chronic Myelogenous Leukemia: is 400 mg Daily of Imatinib Mesylate an Optimal Starting Dose for Japanese Patients?

✍ Keisuke Miyazawa; Jiroh Nishimaki; Tomoko Katagiri; Goro Sashida; Nahoko Shoji; 📂 Article 📅 2003 🏛 Carden Jennings Publishing 🌐 English ⚖ 113 KB

Imatinib dose escalation in two patients

Imatinib dose escalation in two patients with chronic myeloid leukemia, with low trough imatinib plasma levels measured at various intervals from the beginning of therapy and with suboptimal treatment response, leads to the achievement of higher plasma levels and major molecular response

✍ Edgar Faber; David Friedecký; Kateřina Mičová; Martina Divoká; Beata Katrincsáko 📂 Article 📅 2010 🏛 Carden Jennings Publishing 🌐 English ⚖ 236 KB